Centanafadine

Unassigned

New Medicines

Attention-deficit hyperactivity disorder (ADHD) in adults

Information

New molecular entity
Neurovance
Neurovance

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Triple neurotransmitter uptake inhibitor (noradrenaline, dopamine, serotonin)
Estimated prevalence of childhood ADHD in the UK is about 2.4% overall [3], with a significant male bias (3.62% vs. 0.85%) [4]. Only about 15% retain the full diagnosis in adulthood, however a further 50% still have some symptoms (partial remission) with continuing functional impairment including psychological, social, or educational difficulties [3].
Attention-deficit hyperactivity disorder (ADHD) in adults
Oral